EUVIMEDEUVIMED entdecken
Crossref

New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure

Toni Herta iD, Christian Gaebler, Johannes Wiegand, Münevver Demir, Frank Tacke

Seminars in Liver Disease · 06.11.2026

DOI: 10.1055/a-2990-0086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Liver Disease, online erschienen am 06.11.2026. Verfasst von Toni Herta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Charité - Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology, Berlin, Germany. Die Arbeit nennt 78 Literaturangaben. Gefördert von: German Research Foundation, ermany's Excellence Strategy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis D virus infection, also known as chronic hepatitis delta, remains the most severe form of chronic viral hepatitis, associated with accelerated liver disease progression, cirrhosis, decompensation, and hepatocellular carcinoma. Recent years have seen major advances in screening strategies and antiviral therapies for hepatitis D. This review discusses evidence supporting broader hepatitis D screening among hepatitis B surface antigen (HBsAg)-positive individuals and practical considerations for implementation across epidemiological settings, and reviews current and emerging treatments—entry inhibition (bulevirtide), prenylation inhibition (lonafarnib), immune-modulatory therapies (pegylated interferons), and HBsAg-targeting approaches (tobevibart, elebsiran, brelovitug, and nucleic acid polymers)—focusing on treatment response and durability of viral suppression. In conclusion, emerging therapies have substantially improved antiviral efficacy, shifting the focus of hepatitis D management from on-treatment suppression toward durable off-treatment control and functional cure, changing the diagnosis, treatment, and long-term management of chronic hepatitis D.

Autor:innen und Institutionen

  • Charité - Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology, Berlin, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany, Berlin.
  • Laboratory of Translational Immunology of Viral Infections, Charité-Universitätsmedizin Berlin, Department of Infectious Diseases and Critical Care Medicine, Berlin, Germany, Berlin.
  • Leipzig University Medical Center, Department of Medicine II, Saxony, Germany, Leipzig.

ORCID-Profile: Toni Herta

Förderung

  • German Research Foundation
  • ermany's Excellence Strategy

Zitieren

APA

Herta, T., Gaebler, C., Wiegand, J., Demir, M., & Tacke, F. (2026). New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure. Seminars in Liver Disease. https://doi.org/10.1055/a-2990-0086

Vancouver

Herta T, Gaebler C, Wiegand J, Demir M, Tacke F. New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure. Seminars in Liver Disease. 2026. doi:10.1055/a-2990-0086

BibTeX
@article{Herta2026,
  author = {Herta, Toni and Gaebler, Christian and Wiegand, Johannes and Demir, Münevver and Tacke, Frank},
  title = {New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure},
  journal = {Seminars in Liver Disease},
  year = {2026},
  doi = {10.1055/a-2990-0086}
}
Kostenlos starten →